Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 4/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403466 | 0.89 | PKM (0.40) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL27788616 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL3397905 | 0.85 | RAB9A (0.33) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL510666 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL28418699 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL509681 | 0.80 | NAMPT (0.42) | NPC1RAB9ASMN1; SMN2HPGDMEN1 | |
| SCHEMBL3405493 | 0.77 | DGAT1 (0.37) | NPC1 | |
| SCHEMBL30554013 | 0.77 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL28034305 | 0.72 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL21051140 | 0.69 | KDM5A (0.40) | CYP1A2CYP3A4CYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| EP-2102199-B1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2011-04-27 | — | — | EP | disclosed |
| EP-2102199-B1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2011-04-27 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| CN-101558066-A | Pyrrole derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2009-10-14 | — | — | CN | disclosed |
| EP-2102199-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008068470-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068470-A1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | TLR5, TLR2, PIR | CYP1A2 252/4885CYP3A4 327/4885CYP2C9 157/4885 |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | NISCH, PAK6, MYD88 | CYP1A2 391/4885CYP3A4 288/4885CYP2C9 201/4885 |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, ABCB11 | CYP1A2 41/4885CYP3A4 28/4885CYP2C9 11/4885 |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | CYP1A2 156/4885CYP3A4 236/4885CYP2C9 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.